Authors
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Dr. Sandler on Immunotherapies to Treat Lung CancerDr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer
Latest:
Expert Discusses Mutations in MelanomaAlan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.
Latest:
Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCLAlan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.
Latest:
3-D Printing Technology Enhances Limb Preservation in Cancer OperationsLimb preservation is now the procedure of choice for the treatment of patients with bone cancer.
Latest:
Challenges of Implementing Alternative Delivery Models for Genetic Counseling in Prostate CancerAlanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.
Latest:
Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell TumorAlbert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.
Latest:
Congress Passed the Stimulus Bill; What Should You Do Now?Physicians who see Medicare patients are practicing in very difficult times.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Montero Discusses PERTAIN Study in HER2-Positive Breast CancerAlberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.
Latest:
Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose TissueAldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.
Latest:
NYU Researchers Target Tumor Cell Metabolism in Pancreatic CancerResearchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.
Latest:
Dr. Koo on Degarelix for the Treatment of Prostate CancerAlec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association, discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.
Latest:
Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted TreatmentAleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.
Latest:
Dr. Sekulic on Molecular Testing in Advanced MelanomaAleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.
Latest:
Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic MalignanciesAlessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.
Latest:
Dr Tedeschi on the Initial Efficacy of Zanubrutinib Plus Venetoclax in Del 17p/TP53–Mutant CLL/SLLAlessandra Tedeschi, MD, discusses the utility of zanubrutinib plus venetoclax in patients with CLL/SLL harboring deletion 17p and/or TP53 mutations.
Latest:
Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial CancerAlessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.
Latest:
Dr. Volpe Discusses the Management of Localized Kidney CancerAlessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.
Latest:
Dr. Adjei on Adverse Events From MEK InhibitorsAlex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Latest:
Dr. Denes Discusses Biosimilar Pricing in OncologyAlex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.
Latest:
Dr Herrera on Nivolumab vs Brentuximab Vedotin Plus AVD in Hodgkin LymphomaAlex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.
Latest:
Alex Molasiotis, RN, PhD, on the Management on BreathlessnessAlex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.
Latest:
Dr. Olawaiye on How to Address Disparities in Cancer CareAlexander B. Olawaiye, MD, discusses how to address disparities in cancer care.
Latest:
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid TumorsDr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.
